Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artificial intelligence spots hidden liver scarring from simple blood tests

NCT ID NCT07675525

Diagnosis Sponsor: Siriraj Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a computer program called NIMIT-AI that analyzes routine blood test results over multiple doctor visits to detect liver scarring in people with fatty liver disease (MASLD). Unlike the current standard method (FIB-4), which often misses cases and fails with incomplete data, NIMIT-AI uses deep learning to spot patterns suggesting fibrosis. The tool was developed using health records from 969 patients at a Thai hospital and showed better accuracy than FIB-4, even when some lab results were missing. No extra tests or procedures were required from patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NIMIT-AI (artificial intelligence diagnostic model)
What this could lead to
If successful, this AI tool could help doctors catch liver scarring earlier in fatty liver disease patients, potentially preventing progression to severe liver damage.
What could go wrong
This is a retrospective study using data from one hospital in Thailand, so results may not apply to other populations. The AI needs prospective validation before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,351 people

The number who actually took part.

Started

Jan 2018

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) receiving outpatient hepatology care at Siriraj Hospital, a 2,500-bed tertiary academic medical centre in Bangkok, Thailand. The population reflects a high metabolic comorbidity burden typical of urban Thai patients, with elevated rates of type 2 diabetes, obesity, and cardiometabolic multimorbidity.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years at index visit * Confirmed MASLD diagnosis per Delphi consensus criteria * At least one outpatient visit with concurrent laboratory data and FibroScan liver stiffness measurement within observation window (2018-2022) * Receiving care at Division of Gastroenterology, Faculty of Medicine Siriraj Hospital, Mahidol University Exclusion Criteria: * Alternative chronic liver disease aetiology (autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis) * Chronic viral hepatitis (hepatitis B or C surface antigen positivity) * Prior liver transplantation * Active extrahepatic malignancy at baseline * Insufficient longitudinal data for outcome ascertainment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Masld (metabolic dysfunction-associated steatotic liver disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Masld (metabolic dysfunction-associated steatotic liver disease)

Contacts and locations

Locations

  • Faculty of Medicine Siriraj Hospital

    Bangkok Noi, Bangkok, 10700, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.